SPECTRUM PHARMACEUTICALS INC
BioSniper Score
4-factor signal
Market Cap
—
Cash Runway
9.9 mo
Lead Asset
chemotherapy (Phase 2)
Next Catalyst
—
SPECTRUM PHARMACEUTICALS INC: 4 pipeline candidates · 7 clinical trials · 1 FDA decision · Updated within the last hour.
Go deeper on SPECTRUM PHARMACEUTICALS INC with Spotter
Ask follow-up questions and run a full multi-agent deep dive on SPPI — live, with citations.
Score breakdown4-factor signal · derived from public data
9.9 months
D/E 3.02 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Key Financialsas of March 31, 2023
Cash
$52.4M
Quarterly Burn
$21.4M
Revenue
$15.6M
Free Cash Flow
-$21.5M
Total Liabilities
$80.9M
Shareholders Equity
$26.8M
Current Ratio
2.71
Commercialization & Governance
Commercialization
- Status
- Commercial
- Has Revenue
- Yes
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| chemotherapy | Phase 2 |
| eflapegrastim | Phase 2 |
| poziotinib | Phase 2 |
| rolvedon | Approved |
Frequently asked questions
What is SPECTRUM PHARMACEUTICALS INC's lead drug candidate?
SPECTRUM PHARMACEUTICALS INC's most advanced tracked candidate is chemotherapy (Phase 2) for Solid Tumors.
What therapeutic areas does SPECTRUM PHARMACEUTICALS INC focus on?
SPECTRUM PHARMACEUTICALS INC develops therapies across Oncology, Respiratory, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.
Get the full picture on SPECTRUM PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.